Application of allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia in the era of targeted therapy / 白血病·淋巴瘤

ABSTRACT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the main curable therapies for patients with acute lymphoblastic leukemia (ALL). This article discusses the status of allo-HSCT for ALL as well as how to combine targeted therapy with allo-HSCT to improve outcomes of ALL in the era of targeted therapy based on the data obtained from the 63rd American Society of Hematology (ASH) Annual Meeting.